Prot. 20-HMedIdeS-17: An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using

Project: Research project

Project Details

StatusActive
Effective start/end date1/26/22 → 1/26/25

Funding

  • CTI Clinical Trial and Consulting Services (Prot# 20-HMedIdeS-17)
  • Hansa Biopharma AB (Prot# 20-HMedIdeS-17)